Ulcerative colitis and Crohn's disease are inflammatory bowel diseases (IBD) that lead to chronic inflammations of the gastrointestinal tract due to an abnormal response of the immune system. Finding new effective drugs to tackle IBD represents a major therapeutic concern since IBD incidence and prevalence is increasing worldwide. Recent studies positioned Cortistatin (CST) as a candidate for IBD treatment due to its anti-inflammatory and immunomodulatory activity. Here, we studied the structural properties of CST using NMR and synthesized and characterized new analogs displaying enriched populations of some native conformations. One of them, Analog 5, preserved the activity against IBD with an increased half-life in serum, overcoming the native hormone limitation and opening the door for the use of CST analogs as therapeutic agents. This work represents a new approach to the rational design of molecules to treat IBD and a possibility for patients that fail to respond to other therapies.
Graphical abstract Introduction
The gastrointestinal tract is a complex system where factors such as diet, environmental and/or microbial inputs challenge the immune system continuously 1 . When these factors dysregulate the gastrointestinal immune system-specially in genetically predisposed individuals -, the perturbation gives rise to inflammation and other symptoms collectively known as Inflammatory Bowel Disease (IBD). In fact, IBD covers a broad spectrum of pathologies and disease severities, including Ulcerative colitis (UC) and
Crohn's disease (CD) that lead to chronic inflammations. The underlying mechanisms involved in these diseases are not fully understood although these mechanisms correlate with elevated levels of pro-inflammatory cytokines, tumor necrosis factor-α (TNF-α), interferon-g (IFN ) as well as with interleukin 2 (IL-2) 1,2 . In most instances, there is no cure currently available, thus turning IBD into chronic conditions, which often impact the quality of life of the patients. Altogether, these observations position IBD as a major health concern whose treatment is an important priority for our society. Finding specific and safe therapeutic tools to tackle these complex disorders is not trivial and requires an efficient combination of approaches to increase treatment effectiveness, improve patient quality of life and reduce the economic cost 3 .
The current treatment pipeline includes amino-salicylates, corticosteroids, immunomodulators and anti-TNFα antibodies and surgery 4 . Anti-TNF agents have been a major advance as they have proven to be quite effective for both UC and CD but still, onethird of the patients are not responding to the treatment 5 . In this regard, the main challenges that patients face are disease progression, uncontrolled and relapsing inflammation, the appearance of important side-effects in long-term treatments and the high economical cost of them (over $20 billion every year in the USA) 6 . Therefore, finding new molecules to use in combination with, or as alternatives to currently available drugs presents itself as a major need in the field. Several years ago, cortistatin (CST), a neuro-peptide hormone 7, 8 was found to play immunomodulatory roles 9 and its external administration protected mice models of IBD from colitis development 10 . In addition, CST mRNA was detected in many neuroendocrine tumors of the lung, and in neuroendocrine tumors of the gastrointestinal tract 11, 12 . These evidences place CST as an important signaling molecule of the gastrointestinal track.
Moreover, CST was shown to inhibit the in vitro production of inflammatory mediators in activated macrophages, revealing that CST -in contrast to somatostatin-, is an effective agent against hapten-induced CD 11, 12 . Cortistatin sequences (human, mouse and rat) are highly similar to that of human somatostatin (SST, Fig. 1a ), another natural peptide hormone known to display a broad set of biological actions and a subject of research for many years 13 . These anti-inflammatory effects would be explained by the regulation of cytokines mediated by CST, decreasing the release of pro-inflammatory and cytotoxic cytokines such as TNFα, IFNγ, IL-2, IL-6 or NO, while stimulating the production of antiinflammatory IL-10. However, the potential application of CST as a therapeutic agent for IBD is limited due to the short lifespan (two minutes in serum) that this peptide exhibits.
Despite the sequence similarity of CST and SST, both hormones respond to different stimuli and display different functions. Remarkably, they both bind to the same set of SST receptors (SSTR1-5) 14 . They also share similar limitations in stability, which preclude their direct pharmacological application. In the case of SST, these limitations were overcome by designing new SST analogs containing non-native amino acids and/or by reducing the peptide length. Some of these analogs, such as octreotide (Sandostatin®), lanreotide (Somatuline®), vapreotide (Sanvar®) and pasireotide (Signifor®) have successfully reached the market.
Considering that the pharmacophore features of CST are unknown, we contemplate the possibility of improving its stability and immuno-regulatory properties by introducing non-native amino acids at specific possitions -as previously done for SST-while maintaining the full-length peptide chain ( Fig. 1b ). To assist the rational design of the mutations, we first studied the conformations of the native hormone in solution by nuclear magnetic resonance (NMR). We found that, although the peptide is conformationally flexible, we could observe different aromatic clusters in solution whose conformations were in equilibrium. We hypothesized that these distinct clusters might correlate with the hormone's function and set to design new analogs that could potentially populate some of these clusters as the main conformation in solution. Among the new peptide analogs designed and tested ( Fig. 1c ), we observed that analog 5 displayed the anti-inflammatory activity showed by the native peptide in two established preclinical models of IBD 15 . The activity was of the same order of magnitude than that of the anti-TNFα antibody and mesalazine (reference treatments), used for comparison. Moreover, by solving the structure of this analog, we have been able to correlate one specific aromatic cluster with cortistatin's anti-inflammatory activity.
Our work provides a new framework to design new compounds to treat IBD. These compounds have scafolds based on the natural hormone cortistatin, thus maintaining its immunoregulatory activity while displaying improved stability and specificity with respect to the natural hormone in models of IBD.
Results

Conformational properties of Cortistatin in solution by NMR
In contrast to the wealth amount of conformational studies available for somatostatin and its analogues [16] [17] [18] [19] [20] [21] [22] , there is no information describing the conformations of cortistatin in solution to date. To bridge this gap, we synthesized cortistatin (peptide 1, Fig. 1b ,c) using standard Fmoc/ t Bu solid-phase peptide synthesis (as described in the methods and in Supplementary Fig. 1 ) 23 , and studied its folding properties in solution by NMR.
The 2D NMR spectra (experimental section) for this peptide were fully assigned 24 and the structures were calculated using a manually nuclear Overhauser effects (NOE) assignment protocol in Crystallography & NMR system (CNS) 25 . The pair of conserved cysteine residues enables the peptide to form an internal disulfide bond and a cyclic peptide structure with both N-and C-terminus on one side of the molecule. CST populates an ensemble of conformations in solution, as deduced from the presence of nuclear Overhauser effects (NOEs) between residues separated by more than three residues in the sequence ( Fig. 2a ). In addition to those NOEs, we also detected additional ones between the side chains of Trp7 and Lys8, denoting the presence of a type II β-turn, at the other side of the disulfide bridge. These same residues and the turn are also observed in SST 26 . Moreover, weak NOEs were detected between protons of the phenylalanine rings, some of them incompatible with a unique spatial arrangement, confirming the presence of different aromatic clusters in solution. Indeed, the conformational ensemble of CST contains subfamilies of structures mainly defined by the presence of two aromatic clusters, where either two or three aromatic Phe residues pack together ( Fig. 2b-d ).
Overall these results suggest that different sets of conformations can be adopted by the native hormone in solution, and perhaps, in a context dependent environment, these different orientations might be specifically selected by distinct protein/receptor partners in order to regulate cellular responses.
De novo design of cortistatin analogs
Encouraged by these results we designed new CST analogs, envisioning the possibility that they could individually populate -as the main conformation-each of these aromatic clusters ( Fig. 1b ,c, analogs 2-6). We also aimed to correlate the conformations present in the native CST-14 ensemble and in the analogs, with a given observable in our functional assays, enabling the future design of new molecules with immunoregulatory activity and improved stability.
In order to design the first CST analogs, we collected the information described in the literature to optimize the stability and properties of SST. For instance, it is well known that substitution of L-Trp to D-Trp increases the population of the native β-turn, as well as the hormone activity and its half-life in serum 27 . It has also been shown that substitutions of Phe, by L-mesityl alanine (3,5-dimethylphenylalanine, Msa) favored π-π interactions between aromatic rings and increased the overall conformational stability of SST derivatives 19, 20 . For these reasons, in all CST analogs L-Trp was replaced by D-Trp in position 7 and Ser11 was replaced by Thr11 to stabilize the β-turn; and either Phe6 or Phe5 were replaced by Msa (analogs 2 and 4) ( Fig. 1b,c ). In addition to these modifications, terminal residues were acylated as N-octanoyl amides (analogs 3 and 5).
The logic for this modification was to increase the hydrophobicity of the analog and to mimic a similar modification observed in Ghrelin, a hormone produced in endocrine cells in the digestive tracts and that shares with CST the ability to interact with the growth hormone secretagogue receptor GHSR-1a 28 . Finally, a deletion of L-Lys14 (analog 6) was synthesized with the aim of improving the stability of the analogs, as this deletion was identified as the main degradation product of the native hormone by Mass Spectrometry.
All analogs were prepared by standard Fmoc/ t Bu solid-phase peptide synthesis (SPPS) as the wild type CST peptide. The Fmoc-protected Msa was synthetized by asymmetric hydrogenation following our previously described protocol 29 . For the NMR structural studies, the peptides were used as TFA salt and for the in vitro and in vivo studies the TFA counter ion was replaced by acetate salts using ion exchange chromatography.
Half-life in serum and in vitro activity of the new analogs
The stability of the natural CST-14 hormone and of the new analogs was evaluated measuring their half-life in serum and their in vitro affinity by analyzing their binding ability to Somatostatin receptors. Modification of the native cortistatin peptide significantly increased its half-life in serum going from 2 min (cortistatin) to 21 min and 2100 min for analogs 5 and 6 respectively. These results indicated that substitutions introduced in these analogs resulted in at least a 10-fold increase of stability with respect to the native neuropeptide. In fact, the main metabolite of peptide 5 is peptide 6.
Unfortunately, the lack of Lys14 in analog 6, also reduced its aqueous solubility, limiting its use in our functional and structural assays.
Since cortistatin binds in vitro with nanomolar affinity to the five known Somatostatin receptors, we set to investigate if the new analogs maintained similar profiles 19, 20, 22, 30, 31 .
Our results corroborate these findings and reveal that both native hormones and analogs 2-3 have similar profiles and a high preference towards receptor 2, as all SST analogs currently in the market. Remarkably, analogs 4 and 5 have distinct binding preferences for SST receptors (Table 1 ). Analog 5 exhibits a binding preference for receptors 3 and 5.
Analog 5 binding to receptor 4 is close to that of SST, and binding to receptor 2 is much lower when compared to both native CST and SST hormones.
We then moved to evaluate the potential immunosuppressive and anti-inflammatory effects of our peptides in two in vitro assays previously established 15, [32] [33] [34] . Analogs 2, 3 and 4 showed no effect on the inflammatory responses in activated lymphocytes and macrophages ( Table 2) . Conversely, CST and its analog 5 strikingly reduced the production of both the inflammatory mediators TNFα, IL-6 and nitric oxide (NO) by murine macrophages activated with a bacterial endotoxin (lipopolysaccharide, LPS) and reducing the proliferative response and the production of cytokines IFNg and IL-2 by activated mouse spleen cells as well ( Table 2 ).
Our results indicate that analog 5 showed the best results both in anti-inflammatory and immunosuppressive assays as well as in stability in serum and displayed a preference for receptors 3, 4 and 5, different from native SST and CST hormones that preferentially select receptor 2.
Analog 5 as a promising candidate in the treatment of IBD
Once the immunosuppressive activity of analog 5 in vitro was confirmed, we next investigated its potential therapeutic action in two established experimental models of acute and chronic colitis induced by oral administration of dextran sulfate sodium (DSS) and by intrarectal infusion of 2,4,6-trinitrobenzene sulfonic acid (TNBS), which displays clinical, histopathological and immunological features of human UC and CD, respectively 32, 33, 35 .
In the DSS model, intestinal inflammation results from the impairment of the intestinal epithelial cell barrier function by DSS, subsequent exposition of the submucosa to various luminal antigens (bacteria and food) and activation of the inflammatory cells involved in the innate immunity. By 7 days, oral administration of 5% DSS resulted in a progressive increase in the disease activity index, characterised by acute colitis, bloody diarrhoea and sustained weight loss resulting in 50% mortality (Fig. 3a) . Colitis was correlated with dramatic signs of colon damage and inflammation, characterised by colon shortening and increased organ weight (Fig. 3a ). Systemic treatment with analog 5 during three days avoided mortality, ameliorated body weight loss, and improved the wasting disease and colon inflammation, similarly to native cortistatin (Fig. 3a) .
Treatment with analog 5 was also effective in a remitting-recurrent model of ulcerative colitis induced by administration of 3% DSS in two cycles. Subcutaneous injection of analog 5 during the first acute peak of colitis significantly reduced the clinical activity, as shown by improvement of stool consistency, less rectal bleeding, decrease in colon shortening, amelioration of colon damage and improvement in survival rate, and conferred significant resistance to disease activity during a second cycle of DSS administration (Fig. 3b) . A second injection of analog 5 during the second cycle of DSS infusion almost completely abrogated the clinical signs (Fig. 3b) . Remarkably, treatment with analog 5 was even more efficient than a therapy of reference based on a neutralizing anti-TNFα antibody ( Supplementary Fig. 3 ). (Fig. 4a ). Interestingly from a therapeutic point of view, treatment with analog 5 in a curative regimen at the peak of the disease also resulted significantly effective reducing clinical signs and improving survival (Fig. 4b) , showing even better effects than those with reference treatments, such as a neutralizing TNF therapy or oral administration of mesalazine ( Supplementary Fig. 4a ). We observed that both intraperitoneal and subcutaneous administration pathways showed similar effectiveness whereas oral administration was less effective ameliorating TNBS-induced acute colitis ( Fig. 4b) . Interestingly, in a model of chronic colitis induced by repetitive weekly infusion of low doses of TNBS, an initial injection of analog 5 during the first week significantly protected from subsequent expositions to TNBS ( Fig. 4c ), suggesting the induction of a kind of tolerance to disease recurrence. However, treatment with mesalazine or with anti-TNFα antibody fully or partially failed to induce this tolerance effect ( Supplementary Fig.   4b ). As expected, repetitive treatments with analog 5 after each TNBS infusion almost completely reversed disease evolution ( Fig. 4c ), in a similar way than that resulted from chronic administration of mesalazine or repetitive injections of anti-TNFα antibody ( Supplementary Fig. 4b ).
Overall, these results in animal models position analog 5 as a potential candidate in the treatment of IBD.
Conformational studies of Cortistatin and its analogs by NMR
With the aim to understanding the different activity profiles of these analogs we have oriented edge-to-face, and with the aromatic rings of Phe6 and 10 arranged offsetstacked, all pointing away from the D-Trp7:Lys8 pair ( Fig. 5a, Supplementary Fig. 5 ). These NOEs were also present in the native SST hormone 1 but are more intense in analog 5 ( Fig. 2c,d ), suggesting that this analog displays an enriched set of conformations already present in the pool of conformations sampled by the native hormone.
The backbone superposition of the 15 best structures (according to structure validation tests and energy values) is shown as Fig. 5b whereas the side chain orientation of some selected amino acids and all sidechains are shown in Fig. 5c,d . The orientation of the octanoyl moiety is not restrained in the calculation since only few and weak NOEs were observed from the octanoyl residue to Lys4/12 side chains. Remarkably, it seems that both Lys4 and Lys12 side chains shield the octanoyl moiety from the rest of the peptide surface ( Fig. 5a) , defining a hydrophobic pole adjacent to the aromatic cluster located in the middle of the structure. These hydrophobic areas do not prevent the peptide from being soluble but might enhance the interaction with CST natural binders/receptors in a cellular context, explaining why this analog is more active than analog 4, (identical in sequence to 5 but lacking the octanoyl moiety).
We also characterized the conformational properties of analogs 2, 3 and 4. NMR data acquired for them revealed a pattern of NOEs similar for these three analogs but different from analog 5. In these cases (Fig. 6a,c,e ), the aromatic residues 5 and 10 aligned on one side of the molecule, whereas the side chain of residue 6 is located on the other side of the peptide plane. In this conformation, D-Trp7 is close to the pair of aromatic rings 5 and 10, due to the presence of weak NOEs involving the ring protons of D-Trp7 and the methyl protons of Msa5. Among the three analogs, analog 3 that also contains an octanoyl moiety and the Msa at position 6 is less rigid than analogs 2 and 4 ( Fig. 6b,d, 
Discussion and Conclusions
IBD is an emerging global disease and its impact is increasing in children and adolescents. Its rapid development runs along with demographic shifts (urbanization) and an impact of environmental factors (diet, microbiota and psychological stress).
Cortistatin is expressed in immune cells and it has been shown to be a potent antiinflammatory agent that can deactivate some of the IBD responses in animal models 10 .
However, the native sequence has other roles in modulating the GH-releasing activity of Ghrelin and parallels some roles of SST. We have expanded the repertoire of molecules that can help treating patients, designing analogs that retain the anti-inflammatory capacity of the hormone, with increased stability. These new analogs were the result of introducing native and non-native amino acids and other modifications into the native scaffold. We found that analog 5 displayed a ten-fold stability increase in serum while preserving the pattern of immunosuppressive and anti-inflammatory activity of cortistatin. This analog 5 contains a Msa in position 5 and an octanoyl moiety at the Nterminus as main modifications of the native sequence.
With respect to binding to SST receptors, cortistatin is known to interact with all of them in the low nanomolar range 7 . Our results corroborate these findings and reveal that analog 5 has a distinct binding preference for SST receptors, selecting receptors 3, 4 and 5 instead of receptor 2. This observation opens the possibility of using this analog to inhibit prolactin secretion in prolactin-secreting adenomas since these roles are ascribed to specific functions of the SST receptor 5 36, 37 . Certainly, additional experiments are required to test this hypothesis.
The immunosuppressive and anti-inflammatory activities of the analogs were measured using cytokines and inflammatory factors in vitro and corroborated by experiments performed in mouse models of IBD. Because analog 5 mimicked the immunosuppressive activity of cortistatin in vitro, it is plausible that the effect observed for analog 5 in experimental colitis is exerted by regulating the two pathological components of IBD, i.e., exacerbated mucosal inflammation and Th1-driven self-reactive responses, as previously described by cortistatin 9, 10, 38 . Our results revealed that treatment with analog 5 was more effective than the administration of the anti-TNFα antibody used as the reference treatment in these assays, highlighting the potential of this new molecule.
To rationalize the observed biological properties, the new peptides were characterized using NMR, results showing that these analogs populate two main set of conformations in solution. We found that the most active peptide, analog 5, displays an aromatic cluster in solution, defined by contacts between the aromatic rings of Phe6, Phe10 and Msa5 absent in the other analogs. We suggest that receptors or binding partners present in inflammatory cells might recognize epitopes similar to the aromatic cluster found in this analog 5. We believe that our work opens a new path to the rational drug design to help control inflammatory bowel syndromes, using a new family of compounds derived from natural hormones. Fig. 1 Mice received 3% DSS with their drinking water in a cyclic manner. Each cycle consisted of 7 days of DSS followed by a 7-day period without DSS supplementation. Analog 5 (0.4 mg/kg) was injected subcutaneously during the first cycle of DSS on days 3 to 5 (1X), or during the two cycles of DSS on days 3 to 5 and on days 16 to 18 (2X). Disease activity scores and mortality were determined daily and sings of colon inflammation were measured at day 25 or immediately after death of the animal. Mice receiving tap water instead of DSS were used as naïve controls and showed no clinical signs (see supplementary Fig. S3 ). n=8 mice/group. *p<0.05 versus untreated DSS-colitic mice. Analog 5 protects from TNBS-induced acute colitis. Acute colitis was induced in male Balb/c mice by intrarectal administration of TNBS (3 mg/mouse) in 50% ethanol. Mice were treated intraperitoneally (i.p.), subcutaneously (s.c.) or orally (p.o.) three times with analog 5 (A5, 0.4 mg/kg) following a protective regime at 12, 24 and 48h after TNBS infusion (a) or a curative regime 3, 4 and 5 days after TNBS infusion (b). Mice injected intrarectally with 50% ethanol were used as basal controls. Disease evolution and severity was monitored by survival and weight loss (expressed in grams). Colitis score (scale 0-4) was determined at day 4 (protective regime) or at day 6 (curative regime). Macroscopic damage score (scale 0-10) was evaluated in colons isolated at day 10 or immediately after death of animal. c. Therapeutic effect of analog 5 in TNBS-induced chronic colitis. Mice were injected intrarectally once a week with increasing doses of TNBS (0.8 mg/mouse at day 0, 1 mg/mouse at day 7, 1.2 mg/mouse at day 14 and 1.5 mg/mouse at day 21). Analog 5 was injected s.c. at 0.4 mg/kg in saline, following a tolerance regime at days 3, 4 and 5 after TNBS injection or a chronic treatment at days 3, 4, 5, 8, 9, 10, 15, 16, 17, 22, 23 and 24. Mice injected with 50% ethanol on days 1, 7, 14 and 21 were used as basal controls. Disease evolution and severity were evaluated by determining body weight loss, survival, colitis score and the macroscopic colonic damage (at day 28 or after death of each animal). n=8 mice/group. *p<0.05 versus untreated TNBS-colitic mice. a Mouse spleen cells were stimulated with anti-CD3 antibodies (2 μg/mL) in the absence or presence of 100 nmol/L of peptides. Cells incubated with medium alone were used as unstimulated controls. After 48 h, IL-2 and IFNγ levels in the supernatants were determined by ELISA. After 72 h, [ 3 H]-thymidine was added to cultures and proliferation was determined 8 h later by incorporation of thymidine to DNA. Results show mean of three independent cell cultures.
Figures
Tables
b Raw 264 macrophages were stimulated with LPS (1 µg/mL) in the absence or presence of 100 nmol/L of peptides. Cells incubated with medium alone were used as unstimulated controls. After 24h, TNFα and IL-6 levels in the supernatants were determined by ELISA, and nitric oxide levels in the supernatants were assayed by nitrite contents by using a Griess reaction. Results show mean of three independent cell cultures.
Analog 5 values are highlighted in bold for comparison.
